Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - concentrate for solution for infusion - atezolizumab 60 mg/ml - urothelial carcinoma• tecentriq (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumours have a pd-l1 expression ≥ 5%.• tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.- non-small cell lung cancer •tecentriq, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have high pd-l1 expression (pd-l1 stained ≥ 50% of tumor cells [tc ≥ 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering ≥ 10% of the tumor area [ic ≥ 10%]), as determined by an approved test, with no egfr or alk genomic tumor aberrations.•tecentriq, in combination with paclitaxel protein-bound and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc with no egfr or alk genomic tumor aberrations.• tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.• tecentriq is indicated for the treatment of patients with metastatic nsclc who are naïve to anti-pd-l1 or anti-pd-1 therapies and have disease progression during or following platinum-containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on approved therapy for nsclc harboring these aberrations prior to receiving tecentriq.• tecentriq as monotherapy, is indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage ii to iiia nsclc whose tumors have pd-l1 expression on ≥ 50% of tumor cells (tcs).- locally advanced or metastatic triple-negative breast cancer tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumors have pd-l1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.- small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc)."- hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.- melanomatecentriq, in combination with cobimetinib and vemurafenib, is indicated for the treatment of patients with braf v600 mutation-positive unresectable or metastatic melanoma.- alveolar soft part sarcoma tecentriq, as a single agent, is indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (asps).

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - solution for injection - emicizumab 150 mg / 1 ml - emicizumab - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - solution for injection - emicizumab 30 mg / 1 ml - emicizumab - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - entrectinib - hard capsule - entrectinib 100 mg - entrectinib - rozlytrek is indicated for the treatment of adults with solid tumors that:• have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation,• are metastatic or where surgical resection is likely to result in severe morbidity, and• have either progressed following treatment or have no satisfactory alternative therapy.rozlytrek is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are ros1-positive.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - entrectinib - hard capsule - entrectinib 200 mg - entrectinib - rozlytrek is indicated for the treatment of adults with solid tumors that:• have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation,• are metastatic or where surgical resection is likely to result in severe morbidity, and• have either progressed following treatment or have no satisfactory alternative therapy.rozlytrek is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are ros1-positive.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

Israel - engleză - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.